Cannabinoid Dictionary

Evidence from studies involving human participants, kept separate from preclinical and mechanistic evidence.

A valid conclusion when sources are absent, too narrow, inconsistent, or indirect.

Evidence about plausible biological pathways, not proof of consumer benefit.

Human research design that observes associations without randomized assignment.

Animal, cellular, biochemical, or mechanistic work that must stay distinct from human outcomes.

Randomized controlled trial; one study-design term used in evidence summaries.

Receptor-language term for activating a target in a defined model.

Mechanism term for changing signaling through a site other than the main binding site.

Receptor-language term for blocking or reducing activation in a defined model.

Common cannabinoid concept that needs careful source-linked explanation.

Receptor-language term that needs context about model, target, and comparator.

Evidence language for interaction with a target, not automatic clinical effect.

How much of a compound reaches circulation or a target tissue after a given route.

What a compound does at receptors, enzymes, channels, pathways, or tissues.

How a compound is absorbed, distributed, metabolized, and eliminated.

Product-language term that needs formulation, testing, and THC-context links.

Product-testing record that belongs near quality, contaminant, and labeling evidence.

Product-language term that needs clear separation from isolated-compound evidence.

Single-compound product language that should not be mixed with extract evidence.

A safety observation reported in a source, with context about population and product.

A safety topic connecting cannabinoids with medicines, enzymes, or clinical monitoring.

Amount, timing, frequency, and formulation context behind a source-backed row.

Product form, carrier, purity, and mixture details that affect evidence scope.

How oral, inhaled, topical, sublingual, and other routes change interpretation.